Orexo AB Announces Full Implementation of Its ADR Program in the United States Concurrently With Its Commercial Launch of Zubsolv®
9/16/2013 9:22:40 AM
Uppsala, Sweden – September 16, 2013 – Orexo AB (STO: ORX) announced today that
a sponsored level 1 American Depositary Receipt (ADR) program in the United
States has now been fully implemented and the ADRs can now be traded on the OTC
market under the symbol ORXOY. Implementation of the ADR program coincides with
the commercial launch of Zubsolv®, which is the company’s leading product for
maintenance treatment of opioid dependence.
Help employers find you! Check out all the jobs and post your resume.
comments powered by